OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
RLYB
Rallybio Corporation
There isn't enough reported data to score RLYB yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
RLYB Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Stable | |
| Strong | |
| Unavailable |
RLYB's cash flow is currently strong, and its profitability is stable, but its revenue is weak. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over RLYB in the historical PE scenario, which offers more potential upside but is not a forecast.
RLYB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 2.1x | $9.58 | -39% |
| Fair | 2.1x | $9.76 | -38% |
| Expensive | 2.9x | $13.40 | -14% |
| Current | 3.4x | $15.65 | — |
Historical ranges are pointers, not guarantees.
RLYB's PE is 3.4x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
RLYB Forward outlook
There aren't enough analyst estimates for RLYB to show an outlook.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
RLYB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $4.56 | +$6.96 |
| Q2 2026 | $7.92 | +$15.28 |
| Q1 2026 | -$1.37 | +$7.19 |
| Q4 2025 | -$1.59 | +$9.05 |
| Q3 2025 | -$2.40 | +$10.40 |
| Q2 2025 | -$7.36 | +$6.96 |
| Q1 2025 | -$8.56 | +$6.48 |
| Q4 2024 | -$10.64 | +$4.08 |
RLYB has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over RLYB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
RLYB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $212K | 0% |
| Q4 2025 | $222K | +11000% |
| Q3 2025 | $212K | -29% |
| Q2 2025 | $212K | -29% |
RLYB's revenue has slid since its 2024 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -4119% | +442 points |
| Q4 2025 | -2888% | +577512 points |
| Q3 2025 | -3267% | +769 points |
| Q2 2025 | -4744% | +953 points |
| Q1 2025 | -4561% | N/A |
| Q4 2024 | -580400% | N/A |
| Q3 2024 | -4035% | N/A |
| Q2 2024 | -5697% | N/A |
RLYB's operating margin was −4119% last quarter, up 442 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
RLYB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.3M | +$4.3M |
| Q2 2026 | $45.9M | +$54.3M |
| Q1 2026 | -$8M | +$2.2M |
| Q3 2025 | -$6.6M | +$7M |
| Q2 2025 | -$8.4M | +$2M |
| Q1 2025 | -$10.2M | +$5.3M |
| Q3 2024 | -$13.5M | +$2.9M |
| Q2 2024 | -$10.4M | +$3M |
RLYB has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
RLYB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.4% | -82.9K shares |
| 1 year | +1.5% | +82.7K shares |
| 3 years | +13% | +649K shares |
| 5 years | +1049% | +5.2M shares |
| Available history | +106% | +2.9M shares |
RLYB has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
RLYB Net Leverage
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
RLYB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.4 | Neutral |
| Stochastic | 17.7 | Oversold |
RLYB's weekly RSI is 54 (neutral) and its Stochastic is 18 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
RLYB PE vs Healthcare Sector
| Metric | RLYB | Sector median | Relative |
|---|---|---|---|
| PE | 3.4x | 26x | 87% below |
RLYB has the edge over OSCR on valuation relative to its sector.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over RLYB on trend strength, trading above more of its moving averages.
RLYB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $16.3 | 4.1% below |
| 20 week MA | $16.4 | 4.7% below |
| 50 week MA | $12.1 | 29% above |
| 100 week MA | $8.34 | 88% above |
| 200 week MA | $17.4 | 10% below |
RLYB's trend is mixed: it's above two of its five weekly moving averages, and 10% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR's yearly returns have swung widely, from +314% in 2023 to −74% in 2021. It's up 114% so far in 2026.
RLYB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $136.0 | $91.6 | -33% |
| 2022 | $91.6 | $46.0 | -50% |
| 2023 | $46.0 | $19.1 | -58% |
| 2024 | $19.1 | $7.31 | -62% |
| 2025 | $7.31 | $5.50 | -25% |
| 2026 YTD | $5.50 | $15.7 | +185% |
RLYB has the edge over OSCR on returns for 2026, with the stronger performance.